[go: up one dir, main page]

AU2003291402A1 - MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE - Google Patents

MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE

Info

Publication number
AU2003291402A1
AU2003291402A1 AU2003291402A AU2003291402A AU2003291402A1 AU 2003291402 A1 AU2003291402 A1 AU 2003291402A1 AU 2003291402 A AU2003291402 A AU 2003291402A AU 2003291402 A AU2003291402 A AU 2003291402A AU 2003291402 A1 AU2003291402 A1 AU 2003291402A1
Authority
AU
Australia
Prior art keywords
1alpha
mip
csf
adjuvants
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003291402A
Other versions
AU2003291402A8 (en
Inventor
Dan Barouch
Norman Letvin
Paul Mckay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
Beth Israel Deaconess Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center Inc filed Critical Beth Israel Deaconess Medical Center Inc
Publication of AU2003291402A1 publication Critical patent/AU2003291402A1/en
Publication of AU2003291402A8 publication Critical patent/AU2003291402A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55522Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2003291402A 2002-11-07 2003-11-07 MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE Abandoned AU2003291402A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42465802P 2002-11-07 2002-11-07
US60/424,658 2002-11-07
PCT/US2003/035693 WO2004044155A2 (en) 2002-11-07 2003-11-07 MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE

Publications (2)

Publication Number Publication Date
AU2003291402A1 true AU2003291402A1 (en) 2004-06-03
AU2003291402A8 AU2003291402A8 (en) 2004-06-03

Family

ID=32312848

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003291402A Abandoned AU2003291402A1 (en) 2002-11-07 2003-11-07 MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE

Country Status (2)

Country Link
AU (1) AU2003291402A1 (en)
WO (1) WO2004044155A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101119743B (en) * 2005-01-31 2012-09-26 株式会社Eci Immunopotentiating agent
WO2009024426A1 (en) * 2007-07-27 2009-02-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Immunizing compositions for inducing 'bystander' killing of pathogens
SMT202000101T1 (en) 2008-10-10 2020-03-13 Childrens Medical Center Biochemically stabilized hiv-1 env trimer vaccine
WO2012023631A1 (en) * 2010-08-19 2012-02-23 株式会社Eci Pharmaceutical composition for inhibiting proliferation of cancer cells which comprises heat shock protein (hsp) and eci301 polypeptide, and cancer treatment method using same
EA030983B1 (en) 2013-01-07 2018-10-31 Бет Изрейэл Диконисс Медикал Сентер, Инк. STABILIZED HUMAN IMMUNODEFICIENCY VIRUS (HIV) ENVELOPE (Env) TRIMER VACCINES AND METHODS OF USING THE SAME
EP3052132B1 (en) 2013-09-30 2020-07-29 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
EP3052518B1 (en) 2013-10-04 2020-01-08 Beth Israel Deaconess Medical Center, Inc. Stabilized human immunodeficiency virus (hiv) clade c envelope (env) trimer vaccines and methods of using same
PH12017500449B1 (en) 2014-09-26 2022-07-22 Beth Israel Deaconess Medical Ct Inc Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
CN108368157B (en) 2015-12-15 2022-04-15 扬森疫苗与预防公司 Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
EA201892735A1 (en) 2016-06-16 2019-05-31 Янссен Вэксинс Энд Превеншн Б.В. COMPOSITION OF VACCINE AGAINST HIV
AU2017318689A1 (en) 2016-09-02 2019-04-11 Beth Israel Deaconess Medical Center, Inc. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
MA46230B1 (en) 2016-09-15 2020-10-28 Janssen Vaccines & Prevention Bv HIV envelope protein mutations stabilizing the trimeric form
WO2018075559A1 (en) 2016-10-17 2018-04-26 Beth Israel Deaconess Medical Center, Inc. Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
US11229693B2 (en) 2017-06-15 2022-01-25 Janssen Vaccines & Prevention B.V. Poxvirus vectors encoding HIV antigens, and methods of use thereof
JP7253529B2 (en) 2017-07-19 2023-04-06 ヤンセン ファッシンズ アンド プリベンション ベーフェー Trimer-stabilizing HIV envelope protein mutations
EP3797118A4 (en) 2018-05-22 2022-06-29 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
EP3883962A4 (en) 2018-11-21 2023-04-12 Beth Israel Deaconess Medical Center, Inc. ANTIBODY TREATMENTS FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV)
US20240197867A1 (en) * 2021-02-26 2024-06-20 The Feinstein Institutes For Medical Research Neural control of adaptive immunity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935568A (en) * 1995-05-18 1999-08-10 National Jewish Medical & Research Center Gene therapy for effector cell regulation

Also Published As

Publication number Publication date
WO2004044155A8 (en) 2004-08-19
WO2004044155A2 (en) 2004-05-27
WO2004044155A3 (en) 2005-10-06
AU2003291402A8 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
AU2003291402A1 (en) MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
AU2003258714A1 (en) Immune modulatory compounds and methods
WO2003072035A8 (en) Compositions and methods for the treatment of immune related diseases
WO2004041170A9 (en) Compositions and methods for the treatment of immune related diseases
WO2004024097A9 (en) Compositions and methods for the treatment of immune related diseases
AU2003259735A1 (en) Small-mer compositions and methods of use
ZA200602950B (en) Vaccine compositions comprising an interleukin 18 and saponin adjuvant system
AU2008243079A1 (en) Compositions and methods for generating an immune response
AU2002242085A1 (en) Methods and compositions useful for stimulating an immune response
WO2005025604A3 (en) Use of hmgb and hmgb fragments to decrease specific immune response
AU2003299823A1 (en) Methods of inducing and maintaining immune tolerance
AU2003217105A1 (en) Novel of cytokine inhibitors
AU2003270779A1 (en) Vaccine compositions and adjuvant
AU2003303926A1 (en) Ceramics and methods of making the same
AU2003259374A1 (en) Vaccine comprising il-13 and an adjuvant
WO2004024076A8 (en) Novel compositions and methods for the treatment of immune related diseases
AU2003245134A1 (en) Oxytocin as cardiomyogenesis inducer and uses thereof
AU2003302234A1 (en) Immune response associated proteins
AU2003260818A1 (en) Treatment of immune system dysfunction
AU2002361488A1 (en) Field and background of the invention
AU2003239773A1 (en) Preparation of vaccines
AU2003268230A1 (en) Immune response associated proteins
AU2003212475A1 (en) Immune response associated proteins
AU2002240013A1 (en) Chemokines as adjuvants of immune response
AU2003221470A1 (en) Furniture connection system and furniture assembled by use of the connection system

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase